We're thrilled to announce that SKOUT®: real-time AI for polyp detection, will soon be available to gastroenterologists throughout the United States. Learn more about the latest technology for enhanced adenoma detection here: businesswire.com/news/home/2… @provationmed

Iterative Health is excited to announce a partnership with @FLResearchInst to bring AI Recruitment (AIR) technology to Florida, to help democratize access to novel IBD therapeutics for all patients, regardless of where they receive care. @FLDigestive businesswire.com/news/home/2…

We’re on the list! Excited to share that Iterative Health has been included in @BuiltIn's Best Midsize Places to Work List in Boston! #2023BuiltInBest businesswire.com/news/home/2…

Iterative Scopes is now Iterative Health! With this re-branding, we reinforce our commitment to advancing precision medicine and continuing to raise the bar for both accuracy and consistency in physician decision-making. Visit our new website: iterative.health/

Iterative Scopes announces a new partnership with One GI® to bring AI-Recruitment to their clinical research, starting at @Gastro1Memphis. Through this collaboration, both organizations hope to better democratize access to novel IBD therapeutics. @OneGICEO bwnews.pr/3S0bf9w

We’re thrilled to announce that our real-time, computer-aided, polyp detection device SKOUT™ has received 510(k) clearance from the FDA. Read our new release to learn more about our registration study. SKOUT is not yet for sale in the US. @provationmed businesswire.com/news/home/2…

The registration study for our real-time computer-aided polyp detection device SKOUT™ is featured on the cover of @AGA_Gastro! Check out the September issue to read our registration study results. SKOUT is not yet for sale in the US. @provationmed gastrojournal.org/article/S0…

@BuiltInSF recently interviewed our Chief Product Officer Brice Wu to learn what a culture of ownership means for his team. bit.ly/3djHySm

Check out our new video to learn how Iterative Scopes aims to revolutionize gastroenterology by delivering precision medicine and quality care to IBD patients. #ibd

In a video with @MDMagazine, @AasmaShaukatMD discusses data from our DDW 2022 late-breaking abstract showing that SKOUT™ demonstrated statistical superiority at overall adenoma detection compared to routine colonoscopy. Not currently for sale in the US. bit.ly/3vk1mei

Laura Mantell (@lfmantell) joins Iterative Scopes as VP of Life Sciences. In support of the company’s goal to help optimize IBD clinical trials, she will steer all life sciences, biopharma, and biotech partnerships. #artificialintelligence businesswire.com/news/home/2…

This morning, @Clin_Info_News published an article written by Iterative Scopes SVP of Clinical Strategy, Chris Fourment, MD (@c4ment) on the topic, “How AI and Computer Vision Can Solve Challenges in IBD Drug Development” clinicalresearchnewsonline.c… #gastroenterology

Iterative Scopes announced at #DDW2022 that its computer-aided device, SKOUT(™), demonstrates statistical superiority at overall adenoma detection compared to routine colonoscopy.  @AasmaShaukatMD businesswire.com/news/home/2…

At @DDWMeeting 2022, Iterative Scopes presented data created in collaboration with @LillyPad demonstrating how AI can improve endoscopic-disease severity scoring in ulcerative colitis. #DDW2022 businesswire.com/news/home/2…

Iterative Scopes is excited to announce that it has entered an AI-driven data sharing agreement with Pfizer to advance IBD clinical trials. businesswire.com/news/home/2…

Thank you @Nasdaq for highlighting Iterative Scopes and our recent fundraise in Times Square!

Iterative Scopes has entered a collaboration with Janssen Research & Development, LLC (@JanssenGlobal) to augment Janssen’s clinical trials for IBD with the deployment of cutting-edge artificial intelligence (AI) and computer vision tools. businesswire.com/news/home/2…

We are excited to announce that we have raised $150 million in Series B financing to advance AI-driven precision medicine for gastroenterology. This round was co-led by @insightpartners & @ClearlakeCap, and marks a total $182 million raised in 2021. businesswire.com/news/home/2…